Rare disease treatment therapies for a variety of life-limiting illnesses are under investigation, and a small number of commercial products have successfully obtained regulatory approval. The cost of treatment is high, and clinical studies evaluating safety and efficacy are performed predominately in high-income countries. Low- and Middle-income countries have barriers to access research and product development and here is the need of society to participate in strengthening life care support for rare disease treatment.
Following are rare disease treatment where we support patient treatment via CSR support
Leber Congenital Amaurosis (Eye Disorder)
Sickle cell anemia (SCA)
CAR-T cell therapy for leukemia and lymphomas
CSR Programme– Rare Disease treatment is the area where support is required to care patients and reach new therapies to them at minimal cost. In this regard we have adoption programme for CSR perspective.
"Adopt a patient clinical trial"
Adoption policies – We customize and suggest CSR initiative as per your corporate social responsibility fit. Rare disease drug development as its own goal to setup fast track research trials. With engagement of multiple corporate houses through their CSR goals, we engage patients who needs immediate relief with the existing rare disease conditions.
Service profiles -
Copyright © 2023 JAGTARINI - All Rights Reserved.